Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Biotts logo — Proprietary drugs in oncology, diabetology, and pain utilizi...

Biotts

Proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies

Founded 2018 Poland Poland 21 employees Non Equity Assistance Total: $1.50M Biotechnology

General Information

Company Name Biotts
Founded Year 2018
Location Poland Poland +2
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology
Funding Stage Non Equity Assistance
Social

Get notified when Biotts moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Biotts

Biotts, a pioneering Polish-American biotech company, is focused on developing proprietary drugs in oncology, diabetology, and pain by leveraging unique formulations and drug delivery technologies. The company has made significant strides in the field with the breakthrough technology of its universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). This carrier has demonstrated the ability to significantly enhance the bioavailability of active substances, allowing them to penetrate through the skin into soft tissues and bones. Notably, the carrier can be tailored for targeted action in pathologically changed tissues, enabling a reduction in therapeutic drug doses while maintaining efficacy and concurrently minimizing side effects. Furthermore, the system facilitates the transport of one to several active substances, providing opportunities to design multi-component drugs. Biotts, established in 2018, operates within the biotechnology sector and is headquartered in Poland. The company recently secured a Non-Equity Assistance investment on 05 October 2021, with Google for Startups participating as the investor. This strategic investment is expected to fuel the further development and advancement of Biotts' groundbreaking drug delivery technologies and proprietary drugs. With its innovative approach and strong investor support, Biotts is well-positioned to make significant contributions to the biotech industry, potentially revolutionizing the treatment landscape for oncology, diabetology, and pain management.

Taxonomy: biotech company, proprietary drugs, oncology, diabetology, pain management, drug delivery technologies, transdermal drug delivery, pharmaceutical industry, bioavailability, targeted therapy, multifunctional transdermal carrier, transdermal therapeutic system, drug formulation, technical development collaborations

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance •••••• 1 •••• •••• 05 Oct 2021
Series A •••••• 1
Investor
22 May 2020

Biotts Alternatives & Competitors

Biotts vs
Corium International
Corium International

Harnessing proprietary technologies to advance transdermal drug delivery for enhanced therapeutic ou...

Debt Financing
201-500 employees
Biotechnology, Health Care
Biotts vs
Zosano Pharma
Zosano Pharma United States

Live at the Speed of Life

Post Ipo Debt
48 employees
Biopharma, Biotechnology
Compare Biotts vs Zosano Pharma
Biotts vs
Noven Pharmaceuticals
Noven Pharmaceuticals United States

A fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

941 employees
Biotechnology, Health Care

FAQ About Biotts

Proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies
Biotts was founded in 2018.
Biotts is headquartered in Poland.
Biotts operates in the following industries: Biotechnology.
Biotts has approximately 21 employees.
Biotts has completed 2 funding rounds, raising a total of $1.50M. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to Biotts include Corium International, Zosano Pharma, Noven Pharmaceuticals, Ratio, TransPharma Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biotts and Corium International are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Biotts and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes